Texas Weight Loss makes the first purchase easier to understand than the ongoing agreement. Its pricing page lists a $150 initial weight-loss visit, a $110 monthly follow-up visit and semaglutide at $100–275 for a monthly supply, depending on dosage. Those are meaningful disclosures, but they are not an all-inclusive treatment quote. Medication carries an additional charge, prescription eligibility is determined at the visit, and the consulted documentation does not establish renewal, cancellation or refund terms.
For an adult considering enrollment, the central question is therefore not simply whether the clinic offers GLP-1 treatment—it does—but what responsibilities and charges begin after the consultation. This documentary review examines public pages consulted October 19, 2026, including the clinic’s English and Spanish material. Texas Weight Loss describes a Texas clinic network with nutritional support and monthly monitoring. The pages provide a recognizable care outline while leaving important gaps between the advertised service, the medication order and the financial agreement.
At a glance
- Initial appointment
- $150 includes a medical consultation, CMP, TSH, lipid panel, HbA1c and body composition analysis; medication is an additional charge.Sources: [9]
- Ongoing visit
- The $110 monthly follow-up lists consultation, an appetite-suppressant prescription if medically indicated, and four energy-boosting shots—not an express inclusion of the medication itself.Sources: [9]
- Semaglutide price
- The published price is $100–275 for a monthly supply depending on dosage; the listing does not establish an all-in GLP-1 treatment price.Sources: [9]
- Geography and access
- The provider advertises six Texas locations, including Austin, San Antonio and the Houston area; its after-hours telemedicine announcement is expressly limited to Texas residents.
The agreement is less complete than the service menu
Texas Weight Loss presents itself as a medical weight-management business with 20 years of experience and six Texas locations. Those are provider claims, not independently verified operating-history findings. Its site identifies Joseph Sleiman as an MD, FAAFP; this review did not independently verify those credentials. The documented business is broader than a GLP-1 prescription service, combining consultations, laboratory testing, nutritional planning, medication options and injections administered at the clinic.
The brand, the Texas Weight Loss Now name and a support email using the clinic45.com domain appear in the documentation, but their legal relationship is not explained. Before paying, a prospective patient should establish which entity provides care, which collects payment and which handles disputes. The pages identify a service brand more clearly than they identify the legal counterparty responsible for every part of the transaction.
That distinction matters when comparing an appointment booking with a treatment agreement. The consulted pages do not disclose minimum commitments, automatic renewal, required prepayment, cancellation deadlines, refunds or missed-appointment charges. Their absence does not prove that such terms do not exist. It means readers should obtain the applicable enrollment terms in writing rather than treating the marketing pages as a complete contract.
What the first $150 actually buys
The initial weight-loss visit has the clearest published bundle. For $150, the pricing page lists a medical consultation, laboratory work comprising CMP, TSH, lipid panel and HbA1c, and body composition analysis. It also lists four energy-boosting shots, a diet menu, a meal plan and a pantry makeover guide. These are advertised inclusions, not proof that every patient receives or needs every component in exactly the same manner.
The important boundary is explicit: prescription eligibility is decided during the visit, and medication costs extra. Paying for the appointment therefore does not guarantee a prescription or include the drug. The general starting process is a consultation at one of the clinics to discuss goals, review medical history and outline a personalized plan. A separate GLP-1 page describes an evaluation to determine whether those medications may be appropriate.
Readers can use the published bundle to request a precise first-visit confirmation: whether all listed tests will be performed, whether existing results can be used, and whether any additional testing could create another charge. The public documentation does not settle those points. It also does not explain whether an appointment payment would be refundable if medication is not prescribed. That should be resolved before paying, not inferred from the availability of a booking button.
Monthly prices do not establish monthly commitments
The $110 monthly follow-up includes a medical consultation, an appetite-suppressant medication prescription if medically indicated, and four energy-boosting shots. The wording is important: it lists a prescription, not medication supplied at no additional charge. Separately, semaglutide is advertised at $100–275 for a monthly supply depending on dosage. The pricing line does not identify a brand, package presentation or exact formulation, or state that visits are included.
These figures cannot safely be converted into a complete treatment bill. The documentation does not publish a tirzepatide price or resolve possible additional testing, delivery charges or other medication-related fees. It also does not specify insurance billing, accepted payment methods or prior-authorization support. A useful written treatment quote would identify the selected product, its presentation, the visit schedule, separate charges and when each payment becomes due.
Nor does the word monthly establish an automatic subscription, a minimum commitment or a particular billing date. The pages describe a monthly supply and monthly appointments without defining how those transactions connect. The table separates the actual listed charges from unresolved boundaries. Optional injection prices should not be added automatically to a treatment estimate, especially where an appointment package already lists energy-boosting shots.
| Item | Published price and conditions | Boundary to clarify |
|---|---|---|
| Initial weight-loss visit | $150; consultation, specified labs, body composition analysis and listed extras | Medication is an additional charge; prescription eligibility is decided at the visit |
| Monthly follow-up | $110; consultation, prescription if medically indicated and four energy-boosting shots | A prescription listing does not mean medication is included |
| Semaglutide | $100–275 for a monthly supply, depending on dosage | Exact formulation, presentation and combined treatment total are not established |
| Energy-boosting shots | $20 for one or $60 for four | Confirm whether separately purchased shots duplicate visit inclusions |
| Other listed services | “Fat Burner” shots: $25 each or $80 for four; separate body composition analysis: $25 | The four-shot listing carries a buy-three-get-one-free footnote without fuller conditions |
Identify the medication and pharmacy before authorizing an order
Texas Weight Loss advertises injectable semaglutide and tirzepatide, while its Spanish semaglutide material describes subcutaneous administration. Another passage promotes semaglutide with glycine. The documentation does not establish whether all offered semaglutide contains glycine or whether the $100–275 price applies to that particular formulation. A medication name alone is therefore insufficient to identify exactly what a patient would receive, in what presentation, and through which dispensing channel.
A Spanish-language page says its in-house semaglutide comes from a 503b compounding pharmacy but does not name that pharmacy in the cited passage. Its associated quality-control and affordability language is the provider’s commercial claim. The consulted documentation does not independently verify the pharmacy, its location or the exact product. Ask for those details and identify who answers dispensing questions before approving a medication purchase.
FDA approval applies to specific products, not a clinic or pharmacy. Compounded preparations are not FDA approved and do not undergo FDA premarket review for safety, effectiveness and quality; nonapproval alone does not establish clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. That context makes the clinic’s unresolved division of prescribing and pharmacy responsibilities particularly important.
Evaluation requirements are not a promise of eligibility
The clinic describes first-visit blood testing to assess liver, kidney and thyroid function, alongside consultation and body composition analysis. Its FAQ says an EKG is required for patients with risk factors such as hypertension, diabetes or high cholesterol, and for people age 50 or older. The public pricing does not clarify whether an EKG, when required, is included, separately charged or arranged elsewhere. That is a practical pre-appointment question.
The provider’s phentermine criteria should not be confused with its GLP-1 criteria. Its FAQ says patients qualify for phentermine with a BMI of at least 30 and no comorbid condition; a separate phentermine article says people with certain conditions may not be candidates. These are descriptions of the provider’s published phentermine policy, not individualized guidance or a complete GLP-1 eligibility standard. The consulted pages do not establish full GLP-1 criteria or a minimum patient age.
For GLP-1 treatment, the clearest documented commitment is an individualized evaluation rather than guaranteed prescribing. NIDDK explains that medication selection involves health conditions, other medicines, benefits, side effects and costs. A useful consultation should therefore resolve both clinical suitability and practical terms. Readers should ask what happens to their payment if the evaluation leads to a different option, further testing or no prescription at all.
Follow-up has a purpose, but its access rules need detail
Texas Weight Loss asks patients to attend monthly follow-up appointments to review progress, explain results and keep the plan aligned with changing needs. Its GLP-1 page says individualized plans may include nutrition guidance, lifestyle recommendations, monitoring and medication management. The nutrition material describes menus and lists of approved and unapproved foods tailored to lifestyle and preferences. These are documented service descriptions, although the pages do not assign every component a separate price or delivery schedule.
The Spanish semaglutide page also says the team monitors treatment response and helps manage side effects. That is a support promise, but the consulted documentation does not define response times, who receives urgent questions or whether between-visit contacts cost extra. The website provides appointment-scheduling calls to action and a support email, yet the division between administrative and clinical contact remains unclear. Prospective patients should request the actual contact route for each kind of problem.
An after-hours telemedicine announcement is expressly for Texas residents, but it does not publish exact hours, fees, platform details or response times. That geographical restriction belongs to the announced service; it should not be expanded into an unsupported rule for every clinic offering. Similarly, the existence of Spanish-language pages is useful evidence of public information access, not confirmation that every appointment or support channel is available in Spanish.
Home injections leave a delivery question unanswered
The clinic’s FAQ permits self-administration at home after training from its medical team. It also says patients may choose not to receive injections. Those statements distinguish an available treatment route from an obligation to buy shots. They do not, however, establish whether medication is collected at a clinic, dispensed elsewhere or shipped. The consulted pages do not describe shipping charges, refrigeration arrangements, dispatch timing or expected arrival.
Before any home-use order, clarify who supplies the medication and instructions, who provides injection training, and which contact handles a damaged, delayed or questionable package. FDA has received reports of measuring or administration errors with compounded GLP-1 medication, including some associated with hospitalization. Instructions should be clarified with the prescriber or pharmacist, not reconstructed from a review. The public documentation does not establish the clinic’s exact training format or written instruction process.
If an injectable GLP-1 medication arrives warm or inadequately refrigerated, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. That is general FDA guidance, not evidence of a Texas Weight Loss delivery incident. The missing delivery policy also makes financial responsibility worth clarifying: the pages do not explain replacement handling or whether cancellation rights change after a prescription becomes a pharmacy order.
Separate optional extras from the right to stop paying
The service menu extends beyond GLP-1 treatment. Texas Weight Loss advertises phentermine pills, supplements, vitamin B-6 and NAD+ injections, and in-house intramuscular wellness injections including glutathione, B12, Lipoden and amino-acid mixtures. Listing these options does not establish that they are required, included in a GLP-1 plan or appropriate for a particular patient. Ask which services are optional and which, if any, are conditions of the proposed care arrangement.
The posted energy-shot and “Fat Burner” prices are separate offers, with a buy-three-get-one-free footnote attached to the four-“Fat Burner”-shot package. Fuller promotional conditions are not published in the consulted block. The pricing does not establish expiration dates, transferability or refunds for unused injections. Nor should marketing labels such as “energy boosting” or “Fat Burner” be read as independently established outcomes. Provider descriptions and demonstrated clinical effects are different forms of evidence.
Finally, ending appointments, stopping medication purchases and receiving a refund are separate questions. Texas Weight Loss’s consulted pages do not explain any of those procedures sufficiently to describe an exit policy. Before enrollment, request cancellation and refund boundaries, including unused packages, unfilled prescriptions and orders already dispensed. A monthly follow-up recommendation is not proof of a monthly contractual obligation, just as an undocumented cancellation process is not proof that cancellation is unrestricted.
Questions & answers
Does the $150 initial visit include semaglutide?
No. The pricing page expressly says medication is an additional charge and prescription eligibility is determined during the visit. The $150 bundle lists consultation, specified laboratory tests, body composition analysis and other services. Semaglutide has its own $100–275 monthly-supply price, depending on dosage. The pages do not establish the complete combined bill.
Is the $110 follow-up an automatic subscription?
The documentation does not establish that. It advertises a monthly follow-up visit and asks patients to return monthly, but does not disclose automatic billing, a minimum term or renewal dates. Confirm whether appointments are paid individually and whether any separate medication arrangement renews automatically. The visit listing includes a prescription if medically indicated, not an express inclusion of the medication.
Which pharmacy supplies Texas Weight Loss semaglutide?
A Spanish-language page describes sourcing from a 503b compounding pharmacy but does not identify it in the cited passage. Another page advertises semaglutide with glycine. Ask for the pharmacy’s name, location, exact formulation and presentation, and confirmation of which product the published price covers. The documentation does not establish that every semaglutide offering contains glycine.
Can patients use injections at home?
Yes, the FAQ says patients can self-administer after training from the medical team. It also says injections can be declined. Neither statement explains how medication reaches the patient, whether delivery costs extra or what replacement policy applies. Confirm the dispensing, collection or shipping process and the contact for product questions before authorizing a home-use order.
Does Texas Weight Loss offer care outside Texas?
The documented clinic network covers Austin, San Antonio and multiple Houston-area locations. Its after-hours telemedicine announcement is explicitly limited to Texas residents. The consulted material does not establish a broader out-of-state service policy. Readers outside Texas should not assume eligibility based on the existence of telemedicine, and Texas residents should confirm the announcement’s current hours and charges.
What should patients request before paying for ongoing care?
Request a written breakdown of the follow-up fee, medication, required testing and optional injections, together with payment dates and the cancellation and refund policy. Ask which business handles billing and which pharmacy fills the prescription. The published visit and semaglutide prices provide a starting point, but do not resolve insurance handling, automatic renewal or the cost of the entire care arrangement.
Our assessment
Texas Weight Loss documents a substantive clinic-based offering: an itemized initial evaluation, monthly follow-up, nutritional planning and several medication options. Its published visit prices and semaglutide range are more useful than an unspecified starting price. The contractual picture is nevertheless incomplete. The consulted documentation does not identify the compounding pharmacy, connect the advertised formulations to a precise price, or explain ongoing billing, cancellation, refunds and delivery responsibilities. A reasonable next step is to obtain those terms and an itemized quote before making an ongoing purchase. The website supports evaluating this provider further; it does not, by itself, supply a complete treatment agreement or establish clinical outcomes.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Texas Weight Loss — faq ↗
- Texas Weight Loss — phentermine what to know for safe effective weight loss ↗
- Texas Weight Loss — es mx/weight loss supplements ↗
- Texas Weight Loss — official website ↗
- Texas Weight Loss — es mx/weight loss injections ↗
- Texas Weight Loss — glp 1 support ↗
- Texas Weight Loss — pricing ↗
- Texas Weight Loss — weight loss injections ↗
- Texas Weight Loss — es mx/how to inject your weight loss medication ↗
- Texas Weight Loss — how it works ↗